What is the 13F Pro Quality Score for TPST?

13F Pro ranks Tempest Therapeutics, Inc. (TPST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TPST's current score at https://13fpro.ai/company/TPST (free sign-up required for the full ranking).

Where does 13F Pro source TPST data?

All Tempest Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tempest Therapeutics, Inc. files with the SEC under CIK 1544227. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TPST in?

Tempest Therapeutics, Inc. (TPST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TPST research updated on 13F Pro?

TPST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tempest Therapeutics, Inc.(TPST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1544227 TPST stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.7M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

TPST Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Tempest Therapeutics, Inc. (TPST), a Healthcare sector company. TPST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.7m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Tempest Therapeutics, Inc. reports net income of $-5.2M, free cash flow of $-2.8M. Top institutional holders of TPST by reported 13-F value include SABBY MANAGEMENT, Versant Venture Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TPST trades on the Nasdaq exchange and files with the SEC under CIK 1544227. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TPST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tempest Therapeutics, Inc. directly from SEC EDGAR.

✦

Fun facts about Tempest Therapeutics, Inc.

Quirks, history, and lore behind TPST — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
With no approved products and minimal revenue, it runs on grants, collaborations, and capital raises — the classic pre-commercial biotech math of spending more than it earns.
3
The History
Founded in the 2010s, it was built around a focused bet on tumor microenvironment biology — targeting the way cancers hide from the immune system rather than the tumors themselves.
4
The Secret
Its pipeline centers on small-molecule drugs designed to reprogram the immunosuppressive environment around solid tumors, a less crowded lane than traditional checkpoint inhibitors.
5
The Lore
It has explored compounds targeting STING and LXR pathways — decidedly niche science that keeps most casual investors firmly on the sidelines.
6
The Giveaway
Its name evokes a violent storm, its ticker is a weather event in four letters, and its entire mission is brewing up a tempest against cancer.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.2M

Free Cash Flow

Q2 2026

$-2.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+37.2% YoY

$-26.3MFY 2025

FY22 $-35.7MFY23 $-29.5MFY24 $-41.8MFY25 $-26.3M

Operating Income

+36.8% YoY

$-26.6MFY 2025

FY22 $-34.6MFY23 $-29.2MFY24 $-42.0MFY25 $-26.6M

EPS (Diluted)

+83.8% YoY

$-3.17FY 2025

FY22 $-3.09FY23 $-1.91FY24 $-19.50FY25 $-3.17

Total Assets

-59.2% YoY

$16.9MFY 2025

FY22 $46.1MFY23 $51.6MFY24 $41.5MFY25 $16.9M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 $10.4MFY23 $14.8MFY24 $12.8MFY25 $0.00

Op. Cash Flow

+18.8% YoY

$-26.8MFY 2025

FY22 $-31.1MFY23 $-27.4MFY24 $-33.0MFY25 $-26.8M

Free Cash Flow

+19.8% YoY

$-26.8MFY 2025

FY22 $-31.6MFY23 $-27.5MFY24 $-33.5MFY25 $-26.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-26.3M +37.2%	$-41.8M -41.9%	$-29.5M +17.4%	$-35.7M -26.2%	$-28.3M -47.3%	$-19.2M
Operating Income	$-26.6M +36.8%	$-42.0M -44.1%	$-29.2M +15.8%	$-34.6M -28.4%	$-27.0M -39.8%	$-19.3M
EPS (Diluted)	$-3.17 +83.8%	$-19.50 -920.9%	$-1.91 +38.2%	$-3.09 +58.6%	$-7.47 +81.8%	$-41.03
Total Assets	$16.9M -59.2%	$41.5M -19.6%	$51.6M +12.0%	$46.1M -37.1%	$73.2M +220.3%	$22.9M
Total Debt	$0.00 -100.0%	$12.8M -13.7%	$14.8M +42.2%	$10.4M -31.0%	$15.1M +6205.0%	$239.0K
Operating Cash Flow	$-26.8M +18.8%	$-33.0M -20.7%	$-27.4M +12.0%	$-31.1M -19.7%	$-26.0M -36.5%	$-19.0M
Free Cash Flow	$-26.8M +19.8%	$-33.5M -21.6%	$-27.5M +13.0%	$-31.6M -21.2%	$-26.1M -36.8%	$-19.1M

Get alerted when TPST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tempest Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TPST

SABBY MANAGEMENT, LLC
$567.5K511,286 sh
Versant Venture Management, LLC
$299.4K269,772 sh
VANGUARD CAPITAL MANAGEMENT LLC
$259.6K233,888 sh
GEODE CAPITAL MANAGEMENT, LLC
$96.2K86,625 sh
VANGUARD FIDUCIARY TRUST CO
$76.5K68,908 sh
BlackRock, Inc.
$43.4K39,068 sh
Squarepoint Ops LLC
$34.3K30,900 sh
NORTHERN TRUST CORP
$22.4K20,136 sh
CITADEL ADVISORS LLC
$22.0K19,820 sh
UBS Group AG
$6.3K5,636 sh

Fund	Value	Shares
SABBY MANAGEMENT, LLC	$567.5K	511,286
Versant Venture Management, LLC	$299.4K	269,772
VANGUARD CAPITAL MANAGEMENT LLC	$259.6K	233,888
GEODE CAPITAL MANAGEMENT, LLC	$96.2K	86,625
VANGUARD FIDUCIARY TRUST CO	$76.5K	68,908
BlackRock, Inc.	$43.4K	39,068
Squarepoint Ops LLC	$34.3K	30,900
NORTHERN TRUST CORP	$22.4K	20,136
CITADEL ADVISORS LLC	$22.0K	19,820
UBS Group AG	$6.3K	5,636

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TPST on your watchlist

Track score changes the day Tempest Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TPST a good stock to buy?

13F Pro's AI-powered analysis of Tempest Therapeutics, Inc. (TPST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TPST are available on the TPST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TPST is classified as a small company.

Which hedge funds own TPST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TPST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tempest Therapeutics, Inc.'s investment landscape.